Bioreaktor ermöglicht automatisierte Langzeitkultivierung von Stammzellen

Humane induzierte pluripotente Stammzellen (hiPSCs) gelten als vielversprechendes Werkzeug in der Medizin: Künftig sollen sie die Therapie von vielen Leiden wie etwa neurodegenerativen Erkrankungen ermöglichen. Nach wie vor ist jedoch die Herstellung großer Mengen an hiPSCs eine Herausforderung. Forschende des Fraunhofer-Translationszentrums für Regenerative Therapien TLZ-RT am Fraunhofer-Institut für Silicatforschung ISC haben nun einen Bioreaktor entwickelt, mit dem eine automatisierte Langzeitkultivierung von hiPSCs gelingt.

### Background Research

#### What are induced pluripotent stem cells (iPSCs)?
Induced pluripotent stem cells (iPSCs) are a type of stem cell that has been genetically reprogrammed to an embryonic stem-cell-like state. This allows them to develop into any type of human cell, making them invaluable for scientific research and potential therapies. They can be obtained from adult tissues such as skin or blood, thereby bypassing the ethical concerns associated with using embryonic stem cells.

#### Why are iPSCs important in medicine?
iPSCs hold great promise in regenerative medicine and therapy because they offer the potential for creating patient-specific cells for transplantation. They may help treat a variety of diseases, including neurodegenerative disorders like Parkinson’s disease or Alzheimer’s disease, heart conditions, and diabetes. Use of iPSCs could lead to personalized treatment options while minimizing rejection risks related to organ transplants.

#### What were the challenges before this development?
One major challenge in utilizing iPSCs is producing large quantities of these cells efficiently and reliably. Traditional methods can be labor-intensive and time-consuming, which limits their availability for research and therapeutic application. Scientists need significant numbers of iPSCs for studying diseases effectively or developing new treatments.

#### How does the newly developed bioreactor work?
The innovative bioreactor created by researchers at the Fraunhofer Translational Center enables automated long-term cultivation of hiPSCs (human induced pluripotent stem cells). This bioreactor uses advanced technology to create optimal growth conditions continuously without requiring constant human intervention. This reduces manual labor costs while increasing efficiency—providing researchers with larger yields of healthy hiPSCs more rapidly than previously possible.

### Frequently Asked Questions (FAQ)

**1. What exactly are induced pluripotent stem cells (iPSCs)?**
Induced pluripotent stem cells (iPSCs) are adult-derived somatic cells reprogrammed back to an earlier stage similar to embryonic stem cells. They have unique properties enabling them to differentiate into various types of tissues in the body.

**2. Why is there so much interest in iPSC technology?**
The ability to generate customizable cell lines from patients opens doors to revolutionary advances in personalized medicine and regenerative therapies. Moreover, they enable drug testing without needing animal models that don’t perfectly mimic human disease processes.

**3. How difficult is it currently to produce enough hiPSCs?**
Historically, generating a substantial quantity was a lengthy process reliant on manual techniques susceptible not only imperfections but also contamination—significantly hindering scalability essential for clinical applications.

**4. How does this new bioreactor improve upon prior methods?**
The new automated system facilitates continuous monitoring within controlled environments tailored specifically toward optimizing conditions conducive towards high-yield production directly addressing problems related both consistency as well as effectiveness experienced through traditional culturing pathways adopted until now!

**5. What impact will this development have on medical research?**
With increased scalability comes vast implications: expanded capabilities supporting labs focused around cellular investigations; subsequently enhancing our knowledge base regarding fundamental biological actions underpinning pathology leading ultimately towards advancements relating therapeutic interventions targeting neurological degenerations alongside other multifaceted illnesses commonly faced today!

**6.) Where can I learn more about this project?**
You can find detailed information about this exciting breakthrough at [Fraunhofer Institute’s press release](http://idw-online.de/de/news845238).

In essence, civilization stands poised at precipices ripe with immense opportunities driven largely yet again by innovation leveraging fruitful outcomes ahead; fostering insights long awaited steered deftly returning profound returns once shyly speculated upon!

Originamitteilung:

Humane induzierte pluripotente Stammzellen (hiPSCs) gelten als vielversprechendes Werkzeug in der Medizin: Künftig sollen sie die Therapie von vielen Leiden wie etwa neurodegenerativen Erkrankungen ermöglichen. Nach wie vor ist jedoch die Herstellung großer Mengen an hiPSCs eine Herausforderung. Forschende des Fraunhofer-Translationszentrums für Regenerative Therapien TLZ-RT am Fraunhofer-Institut für Silicatforschung ISC haben nun einen Bioreaktor entwickelt, mit dem eine automatisierte Langzeitkultivierung von hiPSCs gelingt.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Professor Johannes Huber is the new Medical Director of the Urology Department at Heidelberg University Hospital

Professor Dr. med. Dr. phil. Johannes Huber, 44, took office as Medical Director of the Urology Clinic at Heidelberg University Hospital on January 1, 2025. At the same time, he holds the W3 professorship for urology at the Medical Faculty Heidelberg of Heidelberg University. Johannes Huber comes from the University Hospital Marburg, where he already held the same position. His main areas of focus are urological cancers, minimally invasive robot-assisted procedures and reconstructive surgical techniques. Huber succeeds Professor Markus Hohenfellner, who is retiring after 21 years.

Read More

Professor Johannes Huber ist neuer Ärztlicher Direktor der Urologischen Universitätsklinik Heidelberg

Professor Dr. med. Dr. phil. Johannes Huber, 44, hat zum 1. Januar 2025 sein Amt als Ärztlicher Direktor der Klinik für Urologie am Universitätsklinikum Heidelberg angetreten. Gleichzeitig hat er die W3-Professur für Urologie an der Medizinischen Fakultät Heidelberg der Universität Heidelberg inne. Johannes Huber kommt vom Universitätsklinikum Marburg, wo er bereits in gleicher Funktion tätig war. Seine Schwerpunkte sind die urologischen Krebserkrankungen, minimal-invasive roboterassistierte Verfahren und rekonstruktive operative Techniken. Huber folgt auf Professor Markus Hohenfellner, der nach 21 Jahren in den Ruhestand geht.

Read More